A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Phase 2 Completed NCT04006145

Condition	NAFLD, NASH
Phase	Phase 2
Sponsor	Albireo
Status	Completed
Enrollment	47 participants
Interventions	Elobixibat, Placebo oral tablet
Start date	Jun 6, 2019
Completion date	Jun 26, 2020
Results posted	Sep 27, 2021

Summary

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)

Change From Baseline in Serum Low Density Lipoprotein-cholesterol (LDL-C) at Week 16

Week 16 · "mmol/L"

Elobixibat	-0.57 ± 0.125 "mmol/L"
Placebo	-0.17 ± 0.134 "mmol/L"

p-value	0.029
LS-Means Difference	-0.40 (95% CI -0.76–-0.04)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский